Posters
Combined umbilical cord patching with amniotic membrane graft for corneal reconstruction
Poster Details
First Author: K.El Mowafi EGYPT
Co Author(s): R. Kamel S. ElTarshoby H. ElSharkawy
Abstract Details
Purpose:
The aim of this study is Evaluation role of umbilical cord patch transplantation for corneal perforations and descemetoceles by assessment of healing of corneal perforation and increased corneal thickness in case with descemetoceles by using slit lamp bio microscopy
Setting:
This study have been held on patients attending to Mansoura Ophthalmic Center, Mansoura University. Egypt in the period from November 2018 till October 2019.
Methods:
Surgical Procedures. After topical anesthesia for cases with corneal thinning patients and general anesthesia in corneal perforation cases. The UCP with epithelium side facing up was fashioned to fit the shape and depth of the ulcer. Finally, a AM graft with epithelium side facing up was applied over the entire cornea as a temporary patch Finally, bandage contact lens was applied. All patients were followed up daily throughout the first week, weekly for 1 month, then monthly for the first 6 months.
Results:
There were 4 eyes of 4 patients with Corneal thinning and 12 eyes of 12 patients with Corneal perforation. The average age for cases with corneal thinning was (66.5±5.45) and the average cases with corneal perforation was (50.58±19.43) years. The follow-up period was 6 months. Best Correction Visual acuity in cases with corneal thinning from (2.505±0.340) by Log MAR to (1.465±0.877). While, in cases with corneal perforation there was a significant improvement of BCVA from (1.0700±0.510) to (0.775±0.282) by Log MAR. Duration for closer of corneal defect in cases with perforation was (4.42±1.56)w
Conclusions:
Our study demonstrates that combining UCP with amniotic membrane transplantation is a promising alternative for corneal insult, providing satisfactory reconstruction and preparing the eye for further keratoplasty operative with prognosis improving post-operative
Financial Disclosure:
None